Fundamental Analysis of MESOBLAST LTD- SPON ADR(NASDAQ:MESO) stock

Fundamental Rating

MESO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. Both the profitability and financial health of MESO have multiple concerns. MESO is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

MESO had negative earnings in the past year.

In the past year MESO has reported a negative cash flow from operations.

In the past 5 years MESO always reported negative net income.

MESO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MESO has a better Return On Assets (-12.22%) than 88.38% of its industry peers.

MESO has a Return On Equity of -16.10%. This is amongst the best in the industry. MESO outperforms 89.06% of its industry peers.

		Industry Rank	Sector Rank
ROA	-12.22%
ROE	-16.1%
ROIC	N/A

ROA(3y)-13.1%

ROA(5y)-12.74%

ROE(3y)-17.23%

ROE(5y)-16.91%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MESO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, MESO has more shares outstanding

MESO has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, MESO has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.23, we must say that MESO is in the distress zone and has some risk of bankruptcy.

MESO's Altman-Z score of 1.23 is fine compared to the rest of the industry. MESO outperforms 65.30% of its industry peers.

A Debt/Equity ratio of 0.22 indicates that MESO is not too dependend on debt financing.

MESO's Debt to Equity ratio of 0.22 is on the low side compared to the rest of the industry. MESO is outperformed by 68.03% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF	N/A
Altman-Z	1.23

ROIC/WACCN/A

WACC8.13%

2.3 Liquidity

MESO has a Current Ratio of 2.71. This indicates that MESO is financially healthy and has no problem in meeting its short term obligations.

MESO has a Current ratio of 2.71. This is in the lower half of the industry: MESO underperforms 69.57% of its industry peers.

A Quick Ratio of 2.71 indicates that MESO has no problem at all paying its short term obligations.

MESO's Quick ratio of 2.71 is on the low side compared to the rest of the industry. MESO is outperformed by 67.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.71
Quick Ratio	2.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MESO have decreased strongly by -21.97% in the last year.

The Revenue for MESO has decreased by -26.56% in the past year. This is quite bad

Measured over the past years, MESO shows a very negative growth in Revenue. The Revenue has been decreasing by -15.43% on average per year.

EPS 1Y (TTM)-21.97%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q28.89%

Revenue 1Y (TTM)-26.56%

Revenue growth 3Y-38.44%

Revenue growth 5Y-15.43%

Revenue growth Q2Q-1.02%

3.2 Future

MESO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 94.71% yearly.

Based on estimates for the next years, MESO will show a very strong growth in Revenue. The Revenue will grow by 143.45% on average per year.

EPS Next Y-278.42%

EPS Next 2Y-102.88%

EPS Next 3Y94.71%

EPS Next 5YN/A

Revenue Next Year-23.16%

Revenue Next 2Y14.73%

Revenue Next 3Y141.74%

Revenue Next 5Y143.45%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MESO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MESO's earnings are expected to grow with 94.71% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-102.88%

EPS Next 3Y94.71%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MESO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (5/17/2024, 7:12:43 PM)

7.35

+0.33 (+4.7%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap838.42M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-12.22%
ROE	-16.1%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.71
Quick Ratio	2.71
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-21.97%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-278.42%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-26.56%

Revenue growth 3Y-38.44%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MESOBLAST LTD- SPON ADR (MESO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens